ArticleFrontiers in oncology2020
Tumor-Associated CD68
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Macrophage membrane-functionalized biomimetic Yiqi Huoxue formula nanoparticles improve atherosclerosis by regulating smooth muscle cell phenotypic transition via the KLF4/NF-κB pathway.Chinese medicine · 2026Article
- Tumor-Associated Macrophage Infiltration and PD-L1 Expression in Gastric Cancer According to a Modified TCGA-Based Classification.Journal of gastric cancer · 2026Article
- Article
- c-MET expression and immune landscape in locally advanced patients with non-small cell lung cancer undergoing radiochemotherapy and consolidative immunotherapy.Translational lung cancer research · 2025Article
- Phenotypic and Spatial Characterization of Tumor-Associated Macrophages in Non-Metastatic Seminoma: Association with Local Tumor Progression.Medical sciences (Basel, Switzerland) · 2025Observational
- The role of RETN in stomach adenocarcinoma (STAD): insights from pan-cancer analysis of RNA-seq data based on the TCGA database.Discover oncology · 2025Article
- Article
- Proteomic characterization of MET-amplified esophageal adenocarcinomas reveals enrichment of alternative splicing- and androgen signaling-related proteins.Cellular and molecular life sciences : CMLS · 2025Article
- Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming.Journal for immunotherapy of cancer · 2025Article
- TAMs and PD-1 networking in esophageal cancer: literature review.ESMO gastrointestinal oncology · 2025Review
- Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.Frontiers in immunology · 2025Review
- The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- Targeting the CSF1/CSF1R signaling pathway: an innovative strategy for ultrasound combined with macrophage exhaustion in pancreatic cancer therapy.Frontiers in immunology · 2024Review
- Case report: A lung squamous cell carcinoma patient with a rareFrontiers in oncology · 2024Article
- Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.Frontiers in immunology · 2024Review
- An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers.EBioMedicine · 2023Article
- The cross-talk between macrophages and tumor cells as a target for cancer treatment.Frontiers in oncology · 2023Review
- The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.Frontiers in immunology · 2023Article
- Prognostic implications of tumor-infiltrating lymphocytes in association with programmed cell death ligand 1 expression in remnant gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.